Deal Watch: Lilly And AZ Team Up In Alzheimer’s In Latest Big Pharma Pairing
Executive Summary
Boehringer Ingelheim signs a cancer immunotherapy deal with CureVac and Endo pursues Auxilium, while Merck KGaA inks multiple deals to add to its dwindling pipeline and Sanofi teams up with MyoKardia in heart disease.
You may also be interested in...
Deal Watch: Auxilium Joins The Tax-Inversion Wave As BIO Keeps The Deal Tide High
Endo expanded its generics business by purchasing Dava, EMD Serono partnered with Mersana on antibody-drug conjugates and Ligand in-licensed a cancer and autoimmune disease candidate from TG Therapeutics. It was all part of a hectic deal-making week coinciding with the annual BIO conference in San Diego.
Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva
It’s become commonplace to see monthly pricing of $10,000 for new cancer drugs, but with competition in mind Boehringer takes a conservative approach with its non-small-cell lung cancer drug Gilotrif (afatinib).
Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely
With the termination of a Phase II trial of LY2887621, Merck’s MK-8931 leads the race to become the first BACE inhibitor approved for Alzheimer’s, although four other companies have similar candidates in earlier stages of development. Lilly says it may continue to pursue BACE inhibition in Alzheimer’s.